<DOC>
	<DOC>NCT03060538</DOC>
	<brief_summary>This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending−dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus. A maximum of approximately 140 participants will be enrolled across multiple sites in the United States. Participants will be randomly assigned to receive study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to 6 weeks), a 12-week treatment period, and a 6-week follow-up period.</brief_summary>
	<brief_title>A Phase Ib Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m2 A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening Current stable treatment (at least 3 months) for diabetes Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0% For women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug For men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm Pregnant, lactating, or intending to become pregnant within 3 months after the last dose of study drug is administered Suspected or confirmed diagnosis of Type 1 diabetes Significant cardiac disease Any psychiatric illness that increases the risk of participation in the study History of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections Poor peripheral venous access Received blood products within 2 months before dosing Donation or loss of blood within 3056 days prior to study drug administration Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody Liver enzymes greater than acceptable limits History of eating disorders or surgical procedures for weight loss Active participation in a structured weight loss or dietary program Treatment with investigational therapy or exposure to any biological therapy Illicit drug use, marijuana use, or alcohol abuse Current use of more than one pack of cigarettes a day or equivalent nicotinecontaining products Any serious medical condition or abnormality in clinical laboratory tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>